A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma.

Trial Profile

A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Thalidomide; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Apr 2008 Study centres added: Mayo Clinic at Scottsdale, Arizona, and Mayo Clinic at Jacksonville, Florida, USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top